

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

Segment wise Revenue, Results and Capital Employed, under Clause 41 of the Listing Agreement

(Rs. lakhs)

	Unaudited		Audited
	3 months ended 31.03.2006	3 months ended 31.03.2005	Year ended 31.12.2005
1. Segment Revenue:			
a) Pharmaceuticals	38065	23574	128635
b) Other Businesses	5322	4468	23066
Total Segment Revenue	43387	28042	151701
Less: Inter Segment Revenue	-	-	-
Net Sales / Income from Operations	43387	28042	151701
2. Segment Results (Profit before Interest and Tax):			
a) Pharmaceuticals	14181	7154	41630
b) Other Businesses	950	523	5199
Total Segment Results	15131	7677	46829
Add/(Less):			
(i) Interest Income (net)	788	548	2345
(ii) Unallocable Income Net of Unallocable Expenditure	38	(130)	(1383)
Total Profit Before Tax and Exceptional Items	15957	8095	47791
3. Capital Employed (Segment Assets less Segment Liabilities):			
a) Pharmaceuticals	14244	19472	11975
b) Other Businesses	8006	8315	7563
Total Capital Employed in Segments	22250	27787	19538

Notes:

- 1 Refer notes 4 and 6 of the aforesaid unaudited financial results for the quarter ended 31st March, 2006.
- 2 (i) The Company is organised into two main business segments, namely:
 - Pharmaceuticals - comprising of bulk drugs and formulations
 - Others - primarily comprising of veterinary formulations, feed supplements, fine chemicals, diagnostics, laboratory equipment and exports mainly relating to pharmaceuticals.

Segments have been identified and reported taking into account, the nature of products and services, the differing risks and returns, the organisation structure, and the internal financial reporting systems.

(ii) Segment Revenue in each of the above domestic business segments primarily includes sales (net of excise duty), processing charges, consignment sales commission, clinical research and data management and export incentives in the respective segments.

(iii) Segment Revenue, Results, Assets and Liabilities include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.